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Abstract
Insulin stimulates tyrosine phosphorylation of insulin receptor
substrate I (IRS-1 ), which in turn binds to and activates phos-
phatidylinositol 3-kinase (PI 3-kinase). In the present study,
we have examined these processes in animal models of insulin-
resistant and insulin-deficient diabetes mellitus. After in vivo
insulin stimulation, there was a 60-80% decrease in IRS-1
phosphorylation in liver and muscle of the ob/ob mouse. There
was no insulin stimulation ofPI 3-kinase (85 kD subunit) asso-
ciation with IRS-1, and IRS-i-associated PI 3-kinase activity
was reduced 90%. Insulin-stimulated total PI 3-kinase activity
was also absent in both tissues of the ob/ob mouse. By con-
trast, in the streptozotocin diabetic rat, IRS-1 phosphorylation
increased 50% in muscle, IRS-i-associated PI 3-kinase activ-
ity was increased two- to threefold in liver and muscle, and
there was a 50% increase in the p85 associated with IRS-1 after
insulin stimulation in muscle.
In conclusion, (a) IRS- -associated PI 3-kinase activity is
differentially regulated in hyperinsulinemic and hypoinsuline-
mic diabetic states; (b) PI 3-kinase activation closely corre-
lates with IRS-1 phosphorylation; and (c) reduced PI 3-kinase
activity may play a role in the pathophysiology of insulin resis-
tant diabetic states, such as that seen in the ob/ob mouse. (J.
Clin. Invest. 1993.92:1787-1794.) Key words: insulin receptor
kinase * insulin resistance - insulin receptor substrate * phos-
phatidylinositol 3-kinase * diabetes
Introduction
Insulin plays a central role in the regulation of blood glucose
levels and acts in a coordinated fashion to stimulate protein
and lipid metabolism by modifying the activity of various en-
zymes and/or transport proteins. Insulin effects at the cellular
level are initiated by binding to the a-subunit of its receptor
with subsequent activation of the tyrosine kinase activity pres-
ent in the f3-subunit ( 1, 2). Substantial evidence has accumu-
lated that the tyrosine kinase activity is instrumental for most
of the downstream biological effects of insulin (3-5). In cul-
tured cells and in the intact animal, insulin receptor activation
leads to the subsequent tyrosyl phosphorylation of a cytoplas-
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mic protein with an apparent molecular mass of 160-185 kD
named insulin receptor substrate- 1 (IRS- 1)' (6-9).
The exact mechanism by which IRS-I links insulin recep-
tors to downstream effects is unknown, but one component of
this link appears to be the enzyme phosphatidylinositol 3-ki-
nase (PI 3-kinase). PI 3-kinase activity is stimulated by a num-
ber of growth factors, including insulin and IGF-1, PDGF,.
EGF, colony-stimulating factor-1, hepatocyte growth factor,
interleukin-2, and nerve growth factor, as well as after cell
transformation ( 10, 11). This enzyme is composed of an 85-
kD regulatory subunit that contains two SH2 and one SH3
domain ( 11), and 110 kD catalytic subunit that phosphory-
lates phosphatidylinositol and its 4' and 4',5' phosphorylated
derivatives in the D-3 position of the inositol ring ( 12). After
insulin stimulation ofcells expressing the human insulin recep-
tor, as well as in liver and muscle of the normal intact rat, PI
3-kinase associates with specific phosphorylation motifs in
IRS- 1 and is activated by this association (8, 9, 13-15).
Insulin resistance is defined as a subnormal biologic re-
sponse to a given concentration ofinsulin. Virtually all patients
with diabetes mellitus, whether affected by insulin-dependent
diabetes mellitus (IDDM1) or non-insulin-dependent diabetes
mellitus (NIDDM), have some degree of insulin resistance (5,
16, 17). In NIDDM, insulin resistance is fundamental to its
pathogenesis. Decreased insulin receptor kinase activity has
been reported in several states of insulin resistance (6, 18, 19).
We recently showed that altered IRS-1 phosphorylation may
have an important role as well (20, 20a). In the present study,
we have examined IRS-1 association with and activation of
PI-3 kinase and the levels of expression of this enzyme in the
hyperinsulinemic, insulin resistant ob/ob mouse and in the
hypoinsulinemic streptozotocin diabetic rat, models of
NIDDM and IDDM, respectively.
Methods
Materials. Reagents for SDS-PAGE and immunoblotting were from
Bio-Rad Laboratories (Richmond, CA). NP-40 was from Calbiochem
(La Jolla, CA). Phosphatidylinositol was from Avanti (Alabaster, AL),
silica gel thin-layer chromatography plates from Merck (Gibbstown,
NJ), protein A-Sepharose 6MB from Pharmacia (Upsala, Sweden),
125I-protein A from ICN Biomedicals (Costa Mesa, CA), [y32P]ATP
from NEN-Du Pont (Wilmington, DE), and nitrocellulose paper (BA
85, 0.2 gm) was from Schleicher & Schuell (Keene, NH). Sodium
amobarbital (Amytal) and human recombinant insulin (Humulin R)
were from Lilly Research Laboratories (Indianapolis, IN). All other
reagents were from Sigma Chemical Co. (St. Louis, MO). Male
Sprague-Dawley rats were from Charles River Breeding Laboratories
1. Abbreviations used in this paper: IDDM, insulin-dependent diabetes
mellitus; IRS- 1, insulin receptor substrate- 1; NIDDM, non-insulin-de-
pendent diabetes mellitus; PI 3-kinase, phosphatidylinositol 3-kinase;
STZ, streptozotocin.
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Inc., (Wilmington, MA). Male C57Bi /6J ob/ob and their lean (ob/
+) controls were purchased from Jackson Laboratory (Bar Harbor,
ME). Polyclonal antiphosphotyrosine antibodies were raised in rabbits
and affinity purified on phosphotyramine columns (21 ). Anti-IRS- I
antibodies were raised in rabbits using a synthetic peptide (CT) derived
from the rat carboxyterminal sequence (TYASINFQKQPEDRQ) of
the rat liver IRS- I protein (8) and IgGs were partially purified with a
protein A-Sepharose column. Anti-rat-PI 3-kinase antiserum (anti-
p85) was from UBI (Lake Placid, NY). Polyclonal antibodies to a
glutathione S-transferase-p85 bacterial fusion protein containing
amino acids 321-724 of the human p85 (22) were produced by injec-
tion into New Zealand white rabbits and purified protein A-Sepharose
chromatography and used in immunoprecipitation experiments.
Animal methods. Male rats ( 130-180 g) and mice (6-8 wk) were
fed standard rodent chow and water ad libitum. Food was withdrawn
12-14 h before experiments. Diabetes was induced in the rats with
streptozotocin in 0.01 M citrate buffer, pH 4.5, administered intraperi-
toneally in a single dose of 100 mg/kg body wt to overnight-fasted rats
and rats were studied 7 d later. Rats and mice were anesthetized with
sodium amobarbital ( 15 and 20 mg/kg of body wt intraperitoneally,
respectively) and were used in experiments 10-15 min later. The ab-
dominal cavity was opened, the portal was vein exposed, and 1 ml of
normal saline (0.9% NaCI) with or without 200 ,g insulin was injected.
Immunoprecipitation with anti-IRS-I and anti-p85 antibodies. 30
and 90 s after insulin injection into the portal vein, liver, and hindlimb
muscle, respectively, were excised and processed for immunoprecipita-
tion experiments as previously described (20). Equal protein amounts
of the supernatant were used in immunoprecipitation experiments
with anti-IRS-I antibodies (9,ug/ml anti-CT) or 2 Mi/ml anti-rat-p85
antiserum and protein A-Sepharose. The samples were processed for
SDS-PAGE electrophoresis and Western blotting as described (20).
The blots were incubated with antiphosphotyrosine antibodies (0.3
Mg/ml anti-pY) or anti-p85 antibodies (whole antiserum 1/200 final
dilution) diluted in blocking buffer overnight at 4°C.
Immunoblotting and activity ofPI 3-kinase. A portion of the left
lobe ofliver and the hindlimb skeletal muscle were removed and imme-
diately homogenized in ice-cold solubilization buffer (1 / 1O wt/vol)
with a generator (Polytron PTA 20S; Brinkmann Instruments, West-
bury, NY) at maximum speed for 30 s and left to sit on ice for 30 min.
The solubilization buffer was composed of 50 mM Hepes (pH 7.5),
137 NaCl, 1 mM MgCl2, 1 mM CaCI2, 2mM Na3VO4, 10mM sodium
pyrophosphate, 1OmM NaF, 2 mM EDTA, 1% NP-40, 10% glycerol, 2
,Mg/ml aprotinin, 10 g/ml antipain, 5 Mg/ml leupeptin, 0.5 Mg/ml
pepstatin, 1.5 mg/ml benzamidine, and 34 ,ug/ml PMSF. Insoluble
material was removed by centrifugation at 15,000 rpm in a rotor
(model 7OTi; Beckman Instruments, Palo Alto, CA) for 50 min. The
supernatant samples were then treated with Laemmli buffer (23) with
100 mM DTT, heated in a boiling water bath for 4 min, and aliquots
(200 ,g of protein) were subjected to SDS-PAGE electrophoresis and
Western blotting as described (20). The blots were incubated with anti-
p85 antibodies (UBI) (whole antiserum 1/200 final dilution) for 4 h at
22°C and washed for 60 min. The blots were then incubated with 2 MCi
of 1251-protein A ( 30 MLCi/Mg) in 10 ml ofblocking buffer for 1 h at 22°C
and then washed again as described above for 2 h. 125I-protein A bound
to the anti-p85 antibodies was detected by autoradiography, and band
intensities were quantitated by optical densitometry (Molecular Dy-
namics, Inc., Sunnyvale, CA).
After insulin injection, a portion ofthe liver and the hindlimb skele-
tal muscle were removed and processed as described above. IRS-I or PI
3-kinase were immunoprecipitated from aliquots of the supernatant
containing 10 mg protein with anti-IRS-i (9 Mg/ml anti-CT) or anti-
human-p85 antibodies (9 Mg/ml) followed by protein A-sepharose
6MB. PI 3-kinase activity in the immunoprecipitates was measured by
in vitro phosphorylation of phosphatidylinositol as previously de-
scribed ( 14).
Other analytical procedures. Plasma glucose levels were determined
with a glucose analyzer (Beckman Instruments) on samples obtained
when the animals were killed. Insulin was determined by a radioimmu-
noassay. Protein determination was performed by the Bradford dye
method (Bio-Rad Laboratories) and bovine serum albumin as stan-
dard (24).
Results
Characteristics ofob/ob mice and streptozotocin diabetic ani-
mals. Table I summarizes the body weight, plasma glucose,
and serum insulin levels ofanimals in all studies. Rats rendered
diabetic by streptozotocin administration were markedly hy-
perglycemic and hypoinsulinemic as compared to controls.
The streptozotocin diabetic rats also gained little or no weight
in the 7 d after the induction of diabetes. By comparison,
plasma glucose and serum insulin levels, as well as the body
weight, were markedly increased in the ob/ob mice compared
to their lean ob/+ controls.
IRS-I phosphorylation and association with the 85-kD sub-
unit of PI 3-kinase in muscle and liver of ob/ob mouse. We
have previously shown that in liver and muscle of the ob/ob
mouse, the phosphorylation of the ,3 subunit of the insulin
receptor and IRS- 1 are reduced. This is accompanied by a de-
crease in the insulin receptor protein level in both tissues, while
IRS- 1 protein levels decrease in liver and increase in muscle
(20). To better define the levels of IRS- 1 phosphorylation, we
performed Western blot analyses of tyrosyl-phosphorylated
proteins in anti-IRS- 1 immunoprecipitates in the basal state
and after in vivo insulin stimulation in the ob/ob and ob/+
control animals. In both liver and muscle of ob/+ mouse, a
phosphotyrosine band with an apparent molecular mass of 185
kD, consistent with IRS- 1, was present in immunoprecipitates
after insulin administration. By comparison, there was almost
no detectable IRS- 1 phosphorylation, even after insulin chal-
lenge in immunoprecipitates from liver or muscle ofthe ob/ob
mice (Fig. 1, A and B).
Insulin stimulated tyrosyl phosphorylation of IRS- 1 is an
essential step in the association with the 85-kD subunit of PI
3-kinase and in the activation of its enzymatic activity (8, 9,
13-15). To examine the association ofthe 85-kD subunit ofPI
3-kinase with IRS- 1, the sanie blot was incubated with antibod-
ies directed against the 85-kD subunit of PI 3-kinase. A band
with the expected molecular mass of the 85-kD subunit of PI
3-kinase was present in all anti-IRS- 1 immunoprecipitates
(Fig. 1, C and D). Furthermore, there was a clear increase in
the amount ofthe PI 3-kinase that coprecipitated with IRS- 1 in
both liver and muscle after insulin administration in the ob/+
mouse, whereas no increase in p85 could be detected in blots
from the ob/ob animals after insulin stimulation.
Table I. Characteristics ofob/ob Mice and STZ Diabetic Rats
Groups n Body weight Plasma glucose Serum insulin
g mg/dl ALU/ml
ob/+ 12 17.7±0.3 141±5 (6) 62.5±11.5 (6)
ob/ob 12 38±0.6 386±57 (6) 282±59 (5)
Control 17 202±4 111±14 (10) 18±3.5 (7)
STZ diabetic 17 169±5 359±18 (14) 4.6±0.5 (6)
The data are represented as the mean±SEM.
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Figure 1. Western blot analysis of tyrosyl phosphorylated proteins and
of PI 3-kinase (85 kD subunit) in anti-IRS-I immunoprecipitates
from liver and muscle of control (ob/+) and (ob/ob) diabetic mice
after in vivo insulin stimulation. The proteins from liver and muscle
were isolated as described in Methods. Mice were anesthetized, and
the abdominal wall was incised to expose the viscera. Normal saline
or 200 ,g insulin was infused into portal vein as a bolus injection,
and 30 and 90 s later, liver and hindlimb skeletal muscle were excised
and homogenized in extraction buffer A at 40C. After centrifugation,
aliquots with same amount of protein were incubated at 4VC with
anti-IRS-I antibodies and protein A-Sepharose. Immunoprecipitated
proteins were analyzed by Western blotting with either antiphospho-
tyrosine antibodies (A and B) or anti-PI 3-kinase (85 kD subunit)
antibodies and '251-protein A, and subjected to autoradiography.
Characteristics of insulin-stimulated IRS-I-associated PI
3-kinase activity of liver and muscle in the ob/ob diabetic
mouse. To determine the impact of changes in IRS- phos-
phorylation and its association with PI 3-kinase, mice were
injected intraportally with insulin and PI 3-kinase activity was
assayed in anti-IRS-I immunoprecipitates from liver and
muscle. A low level of basal PI 3-kinase activity was present in
anti-IRS-1 immunoprecipitates from liver of ob/+ mice
corresponding to a relative specific activity of 3.8±0.6 pmol
phosphate incorporated/mg protein/min. After insulin stimu-
lation there was a rapid five- to sixfold increase in IRS- -asso-
ciated PI 3-kinase activity (P < 0.004) (Fig. 2). In liver of
ob/ob mice, the basal level of PI 3-kinase activity associated
with IRS-I was somewhat increased compared to controls (spe-
cific activity = 7.1±1.2 pmol/mg protein per min), probably
reflecting the markedly increased levels of insulin in the portal
circulation of these mice. However, after insulin stimulation,
IRS- 1-associated PI 3-kinase activity in liver ofthe ob/ob mice
increased only 32% above basal levels (P = NS). Overall, there
was a 90% reduction in insulin stimulated PI 3-kinase activity
in the ob/ob mouse as compared to the ob/+ control (P
< 0.001 ) (Fig. 2).
In muscle the basal level of IRS-1-associated PI 3-kinase
activity was similar in ob/+ and ob/ob mice. Insulin stimu-
lated IRS- 1-associated PI 3-kinase activity > 30-fold in the
lean control animals, whereas in muscle of the ob/ob mice,
insulin stimulated IRS-l-associated PI 3-kinase activity only
- fourfold above basal levels (Fig. 3). Thus, as in liver, muscle
ofob/ob mice exhibited a 90% reduction in insulin-stimulated
IRS-l-associated PI 3-kinase activity as compared to the ob/+
control (P < 0.0001 ).
Total PI 3-activity in the ob/ob mouse. To determine the
extent of insulin stimulation of the total PI 3-kinase activity, a
PI 3-kinase assay was performed on anti-p85 immunoprecipi-
tates from liver and muscle of ob/ob and ob/+ mice before
and after injection of 200 ,gg insulin. Total PI 3-kinase activity
in the basal state was higher in liver ofob/ob mice compared to
ob/+ control animals (S.A. 7.7±1 vs 5.6±0.5 pmol/mg pro-
tein per min), although this difference was not statistically sig-
nificant. Insulin caused a 65 and 80% increase in the PI 3-ki-
nase activity immunoprecipitable with anti-p85 antibodies in
liver and muscle of the ob/+ control animals, respectively. By
contrast, there was no evidence of insulin stimulation in the
total PI 3-kinase activity, as detected by immunoprecipitation
with antibodies directed against the 85-kD subunit of PI 3-ki-
nase, in liver and muscle of ob/ob mice (Table II). Immuno-
blotting experiments on liver and muscle extracts with an anti-
body to the 85-kD subunit of PI 3-kinase revealed a decrease in
the levels of enzyme protein in ob/ob mice to 66±8% (P
< 0.02) and to 75±3% (P < 0.001 ) ofcontrol levels in liver and
muscle, respectively (data not shown). Although these changes
are highly statistically significant, they are not sufficient to ac-
count for the decrease in IRS- 1-associated or total PI 3-kinase
activity. The inability ofinsulin to stimulate the total pool ofPI
3-kinase activity, as well as the IRS- 1-associated pool of PI
3-kinase activity, in both liver and muscle of ob/ob mice fur-
ther emphasizes the importance of IRS-1 phosphorylation in
the association/activation of PI 3-kinase.
We have previously shown that after insulin stimulation in
the normal intact rat, phosphorylated IRS-1 can also be de-
tected is present in anti-p85 immunoprecipitates. To examine
the molecular mechanisms underlying the lack of stimulation
of total PI 3-kinase activity, we performed Western blot analy-
ses on anti-p85 immunoprecipitates from both liver and mus-
cle ofob/ob mice using antiphosphotyrosyl antibodies. In both
muscle and liver, a tyrosyl phosphorylated protein with the
expected molecular weight of IRS-1 was present after insulin
stimulation in ob/ + control animals; this is not observed in the
tissues of the obese ob/ob mice (Fig. 4).
IRS-I phosphorylation and association with the 85-kD sub-
unit ofPI 3-kinase in muscle ofstreptozotocin (STZ) diabetic
rats. As a comparison to the hyperinsulinemic ob/ob mouse,
we performed similar studies in hypoinsulinemic STZ diabetic
rats. Western blot analysis of tyrosyl phosphorylated proteins
in anti-IRS- 1 immunoprecipitates in muscle of STZ diabetic
and control rats revealed a phosphotyrosine band with the ex-
pected molecular weight of IRS- 1 after intraportal insulin ad-
ministration. As previously noted (20), insulin stimulated
IRS-1 phosphorylation was increased in muscle of STZ dia-
betic rats (Fig. 5 A). When the same blot was subsequently
incubated with antibodies directed against the 85-kD subunit
of PI 3-kinase, a band with the expected molecular mass of the
85-kD subunit of PI 3-kinase was present in all anti-IRS-l
immunoprecipitates. There was a twofold increase in the
amount of the 85-kD subunit of PI 3-kinase that coprecipitated
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Table II. PI 3-kinase Activity in Liver and Muscle of Control
(ob/+) and ob/ob Diabetic Mice and Liver ofControl
and STZ Diabetic rats
PI 3-kinase activity
Basal +Insulin Increase above basal
pmol/mg/min
Liver
ob/+ 5.6±0.54 NS 9.18±0.9 iNS 3.54±0.48lP < 0.01
ob/ob 7.72±1.04J 7.77±0.69J 0.05±0.45J
Muscle
ob/+ 6.00±0.58 NS 10.8±1.9 INS 4.8±1.321P<0.04
ob/ob 6.38±0.34J 7.41±0.77J 1.03±0.4 J
Liver
Control rats 1.59±0.07iNS 4.87±0.28 NS 3.26±0.21 INS
STZ diabetic 1.83±0.15J 4.85±0.17J 3.02±0.02J
The proteins from liver and muscle were extracted and incubated at 4VC with
anti-PI 3-kinase antibodies and Protein A-sepharose. PI 3-kinase activity in
the immunoprecipitates was assayed as previously described (14). The results
are expressed as mean±SEM of six separate experiments (ob/+ and ob/ob
mice) and of three separate experiments (control and STZ diabetic rats) each
performed in duplicate.
with IRS-1 in muscle after insulin administration in control
rats (Fig. 5 B). The amount of p85 present in anti-IRS- I im-
munoprecipitates both in the basal state and after insulin stimu-
lation was further increased in STZ diabetic rats compared to
control (Fig. 5 B).
Characteristics of insulin-stimulated IRS-I-associated PI
3-kinase activity ofliver and muscle in STZ diabetic and con-
trol rats. In the extracts of liver from both STZ diabetic and
control rats there was a low level ofbasal PI 3-kinase activity in
anti-IRS-l immunoprecipitates of corresponding to a S.A. of
_ 0.2 pmol/mg protein/min. After insulin stimulation, there
was a fivefold increase in control rats (P < 0.01 ) and a 14-fold
increase (P < 0.05) in STZ diabetic rats in IRS- 1-associated PI
3-kinase activity (Fig. 6 A). Substracting basal activity, there
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Figure 4. Western blot analysis of tyrosyl phosphorylated proteins in
anti-PI 3-kinase (85 kD subunit) from liver and muscle of control
(ob/+) and ob/ob diabetic mice after in vivo insulin stimulation.
The proteins from liver and muscle of ob/+ and ob/ob mice were
extracted, processed, and incubated at 4°C with anti-PI 3-kinase an-
tibody (p85) antibodies and Protein A-Sepharose. Immunoprecipi-
tated proteins were analyzed by immunoblotting with antiphospho-
tyrosine antibodies and '25I-protein A and subjected to autoradiogra-
phy.
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Figure 5. Western blot analysis of tyrosyl phosphorylated proteins and
PI 3-kinase (85 kD subunit) in anti-IRS-l immunoprecipitates from
muscle of control and STZ diabetic rats after in vivo insulin stimula-
tion. The proteins from muscle ofcontrol and STZ diabetic rat were
extracted, processed, and incubated at 4°C with anti-IRS-l antibody
and Protein A Sepharose. Immunoprecipitated proteins were ana-
lyzed by immunoblotting with antiphosphotyrosine antibodies (A)
and anti-PI 3-kinase antibody (p85) antibodies (B) and '25I-protein
A and subjected to autoradiography.
was a threefold increase in insulin stimulated, IRS-i -asso-
ciated PI 3-kinase activity in the STZ diabetic rats as compared
to the controls (P < 0.03). In muscle, IRS- 1-associated PI
3-kinase activity showed a similar pattern (Fig. 6 B). After
insulin stimulation there was a 10-fold increase in IRS- I -asso-
ciated PI 3-kinase activity in control rats, whereas in the STZ
diabetic rats there was almost 20-fold stimulation. This corre-
sponds to a twofold increase in insulin stimulated PI 3-kinase
activity in the STZ diabetic rat compared to control (P
< 0.02). Thus, after insulin stimulation, STZ diabetic rats
showed a significantly higher stimulation of IRS-I-associated
activity in both liver and muscle when compared to control
rats.
Total PI 3-kinase in theSTZ diabetic rat. To determine the
extent of insulin stimulation ofthe total PI 3-kinase activity, a
PI 3-kinase assay was performed on anti-p85 immunoprecipi-
tates from liver of STZ diabetic and control rats before and
after injection of insulin. In the basal state, PI 3-kinase activity
in liver of STZ diabetic and control animals corresponded to
relative specific activities of 1.8±0.15 and 1.6±0.07 pmol/mg
protein per min, respectively. Insulin caused a threefold stimu-
lation ofthe total PI 3-kinase activity in both STZ diabetic and
control animals to a maximal level of - 4.9 pmol/mg protein
per min (Table II). Thus, although IRS- 1-associated PI 3-ki-
nase activity was increased after insulin stimulation in STZ
diabetic rats, insulin stimulated total PI 3-kinase activity was
similar in the two experimental groups. Furthermore, no signifi-
cant changes in the levels of the 85-kD subunit of PI 3-kinase
could be detected by immunoblotting in liver and muscle ex-
tracts of the STZ diabetic rats compared to control rats (data
not shown) and Western blot analysis using antiphosphotyro-
syl antibodies on anti-p85 immunoprecipitates from liver ex-
tracts revealed a band with the expected molecular weight of
IRS- I after insulin stimulation in both STZ diabetic and con-
trol animals of similar intensity (Fig. 7).
Discussion
The molecular events linking the insulin receptor tyrosine ki-
nase to its final cellular actions is a matter ofcontinuing inves-
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Figure 6. IRS- I-associated PI 3-kinase activity in liver and muscle of
control and STZ diabetic rats after in vivo insulin stimulation. The
proteins from both tissues were extracted, processed, and incubated
at 4°C with anti-IRS-l antibodies and protein A-Sepharose. PI 3-ki-
nase in the washed immunoprecipitates was assayed as previously
described ( 17). (A) Liver. The calculated activity of PI 3-kinase (ex-
pressed as pmol phosphate/mg per min incorporated into phosphati-
dylinositol) are as follows: (control): basal = 0.2±0.04, insulin stim-
ulated = 1.0±0.1; (STZ): basal = 0.2±0.1, insulin stimulated
= 2.8±0.72; increase above basal (control) = 0.8±0.1; increase above
basal (STZ) = 2.65±0.72. (B) Muscle. The calculated activity of PI
3-kinase (expressed as picomoles of phosphate per milligram per
minute incorporated into phosphatidylinositol) are as follows: (con-
trol): basal = 0.3±0.1, insulin stimulated = 3.3±1.2; (STZ): basal
= 0.46±0.05, insulin stimulated = 8.4±0.8; increase above basal
(control) = 3.0±1.0; increase above basal (STZ) = 7.9±0.8. The re-
sults are expressed as mean±SEM of four separate experiments, each
performed in duplicate. *Differences from basal level in control rats
at P < 0.05; **Differences from increase above basal level after insu-
lin stimulation in control rats at P < 0.03; ***Differences from basal
level in STZ diabetic rats at P < 0.01.
tigation. Recently, two early steps in the insulin action cascade
have been characterized at a molecular level. First, insulin stim-
ulates tyrosine phosphorylation ofa cytosolic protein ofappar-
ent molecular mass of 165-185 kD termed IRS-I in most (if
not all) insulin responsive cells (6-9). IRS- I fulfills the criteria
of a direct substrate ofthe insulin receptor in vivo and in vitro
(6-9, 13, 14), and consistent with this hypothesis, IRS-I phos-
phorylation is decreased in intact cells expressing kinase-defi-
cient insulin receptor mutants (25, 26). From a biochemical
point ofview IRS- I is characterized by the presence ofmultiple
potential serine, threonine and tyrosine phosphorylation sites
(8). Nine of the tyrosine sites are in the motifs Y(M/X)XM,
which are known to be phosphorylated by the purified insulin
receptor kinase with high affinity (27). Similar Y(M/X)XM
motifs have been identified in a number ofreceptors for growth
factors and several oncoproteins and, when phosphorylated,
have been suggested to serve as intracellular binding sites for
Figure 7. Western blot
Control STZ analysis of tyrosyl-phos-
phorylated proteins in
Mr 205- * anti-PI 3-kinase (85 kD
subunit) from liver of
IRS-1 _ control and STZ dia-
betic rats after in vivo
insulin stimulation. The
proteins from liver of
116 - control and STZ dia-
betic rat were extracted
and processed as de-
scribed in legend of Fig.
80 - 1, and incubated at 4VC
with anti-PI 3-kinase
Insulin + - + antibody (p85) anti-
bodies and Protein
A-Sepharose. Immunoprecipitated proteins were analyzed by immu-
noblotting with antiphosphotyrosine antibodies and '251-protein A,
and subjected to autoradiography.
proteins containing SH2 domains ( 11). Thus, tyrosine phos-
phorylation of IRS- 1 leads to a second intracellular step in
insulin action, an association ofphosphorylated IRS-I with the
enzyme PI 3-kinase (8, 9, 13-15). The association occurs
through phosphorylated YMXM or YXXM motifs on IRS-1
and the SH2 domains on the 85-kD subunit ofthe PI 3-kinase
and results in activation of the catalytic activity of the PI 3-ki-
nase (15, 28, 29). Other SH2 containing proteins, such as
phospholipase-C-y and ras-GTPase-activating protein, which
efficiently bind and activated by the PDGF receptor (30), fail
to interact with IRS- I ( 13), further emphasizing the specificity
of the IRS-i /PI 3-kinase interaction. These data, along with
the time course and the dose response of production of PI 3-P
and the related metabolites PI 3,4-P2 and PI 3,4,5-P3, are con-
sistent with the hypothesis that the PI 3-kinase products may
act as messengers in growth factor action, although their physio-
logic role remains uncertain ( 11 ). We have previously shown a
major impairment in IRS- I phosphorylation in liver and mus-
cle in two animal models of insulin resistance, i.e. the ob/ob
mouse model of NIDDM and the dexamethasone-treated rat
(reference 20 and Saad et al., manuscript submitted for publi-
cation). In the present study, we have examined the associa-
tion/activation of PI 3-kinase with IRS-I in liver and muscle
and total PI 3-kinase activity, in the hyperinsulinemic insulin
resistant ob/ob mouse model ofNIDDM and in the hypoinsu-
linemic streptozotocin diabetic rat.
From the pathophysiological point of view the ob/ob
mouse is characterized by marked obesity, hyperglycemia, hy-
perinsulinemia, and several metabolic defects consistent with
peripheral insulin insensitivity (31 ). The impairment of insu-
lin action in this model is associated with decreased receptor
number (32), but the autophosphorylation ofthe # subunit of
the receptor, as well as the activity of the receptor kinase
against exogenous substrates, when corrected per insulin recep-
tor, appear to be normal (20, 33). In the current study, we find
that both the levels of phosphorylated IRS- I and of the 85-kD
subunit ofthe PI 3-kinase associated with IRS- I are also mark-
edly reduced, and this leads to a marked impairment in the
association/activation of IRS-I with PI 3-kinase after in vivo
insulin stimulation in both liver and muscle of the ob/ob
mouse. Furthermore, while insulin is capable of stimulating a
60-80% increase in the total pool of PI 3-kinase activity in the
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ob/+ control mouse, there is no detectable stimulation of PI
3-kinase in either liver or muscle ofthe ob/ob mouse. Accord-
ingly, tyrosyl-phosphorylated IRS-1 is present in anti-p85 im-
munoprecipitates after insulin stimulation in the ob/+ control
mouse, but not detectable in anti-p85 immunoprecipitates of
the ob/ob mouse. The level of the 85-kD subunit of the PI
3-kinase as detected by immunoblotting were reduced to 66
and 75% of control levels in liver and muscle of the ob/ob
mouse. The levels ofthis protein appear to be inversely related
to circulating insulin levels, suggesting that insulin may play a
role in the regulation ofPI 3-kinase expression. Consistent with
our previous findings (14), the 85-kD subunit of the PI 3-ki-
nase is not tyrosine phosphorylated after insulin stimulation in
either the ob/+ and the ob/ob mouse.
Kelly et al. have recently shown that in rat adipocytes the
majority of insulin stimulated, antiphosphotyrosine immuno-
precitable PI 3-kinase activity is concentrated in the low den-
sity microsomes fraction (34). The low density microsomes
are a heterogeneous membrane fraction enriched also in
GLUT4 glucose transporters (35, 36). These investigators
have hypothesized that PI 3-kinase in the low density micro-
somes is associated with a vescicle that cycles between the
plasma membrane and the intracellular membranes. Interest-
ingly, the 1 0-kD subunit of PI 3-kinase share a significant
degree of homology with VPS34, a yeast protein involved in
vacuolar protein sorting ( 12, 37). A defect in the skeletal mus-
cle glucose transporter translocation in the obese Zucker rat
has been recently described (38). Since the level ofphosphory-
lation ofpp 1 85 (IRS- I ) in response to insulin is lower in adipo-
cytes from humans with NIDDM (6), it is tempting to hypoth-
esize that defective IRS- 1 phosphorylation and PI 3-kinase ac-
tivation in the muscle of the ob/ob mouse may be involved in
the defective glucose transport that is observed in both animal
models (39) and in human NIDDM (40). Thus, the reduced
level ofphosphorylation of IRS- I and the marked impairment
ofthe activation of PI 3-kinase activation after insulin stimula-
tion may play a major role in the insulin resistance observed in
the ob/ob mouse.
Insulin resistance is also observed in humans with IDDM
(16) and in animal models of insulinopenic diabetes despite
increased insulin binding (20). Glucose clamp studies have
mapped the defects in glucose metabolism to both the hepatic
(increased glucose production) and muscular level (decreased
glucose disposal (41, 42). Insulin-stimulated glucose uptake is
reduced when measured in vitro in either isolated or perfused
skeletal muscles from STZ diabetic rats (43, 44). Tissue or
circulating factors such as fatty acids, counterregulatory hor-
mones, and acidosis may antagonize the stimulatory action of
insulin on glucose transport in muscle (45). In vitro studies
have provided conflicting results as to the role of the insulin
receptor kinase in this insulin resistance (46-49). We and
others have recently shown that after acute insulin stimulation
in vivo insulin receptor autophosphorylation per receptor in
liver and muscle ofSTZ diabetic animals is decreased (20, 50).
However IRS- 1 phosphorylation is increased in muscle and in
liver of STZ rats after acute insulin stimulation (20, 50). Con-
sistent with these findings, we now find that after acute insulin
stimulation IRS-1 phosphorylation is increased in muscle of
STZ diabetic rats as compared to controls, and the amount of
PI 3-kinase associated with phosphorylated IRS- 1 is increased
in anti-IRS- 1 immunoprecipitates. Furthermore, insulin-stim-
ulated IRS- 1-associated PI 3-kinase activity is increased two-
to threefold in both liver and muscle of STZ diabetic rats as
compared to controls. Thus increased IRS-1 phosphorylation
is accompanied by a significant increase in IRS- 1-associated PI
3-kinase activity, consistent with an amplification ofthe signal
in the insulin signaling pathway involving 1 subunit autophos-
phorylation, IRS-1 phosphorylation and PI 3-kinase activity.
However, the levels of the 85-kD subunit of PI 3-kinase and
insulin-stimulated total PI 3-kinase activity were similar in
STZ and control rats. These phenomena could be interpreted
as an attempt of target tissues to compensate for the insulin
deficiency and suggest that in the STZ rat, insulin resistance is
neither at the level of IRS- I phosphorylation nor at the level of
PI 3-kinase activation (references 20, 50, and present study).
Recent studies in Chinese hamster ovary cells overexpressing
both IRS-1 and insulin receptors have shown there may be a
delicate balance between the levels ofIRS-1 and insulin recep-
tor in terms of signaling the insulin action cascade (9). Thus,
there is an increase in insulin response when IRS- 1 alone is
overexpressed, but a decrease in insulin response when both
IRS- 1 and insulin receptors are overexpressed simultaneously.
Since IRS-1 contains multiple YMXM/YXXM motifs, it is
possible that hyperphosphorylation of IRS-1 could be detri-
mental, as the density of molecules associated with a single
molecule ofIRS- 1 may be reduced ifthe concentration ofphos-
phorylated IRS-1 is too high to the point where cross-talk no
longer occurs (9).
In conclusion, the insulin resistance observed in vivo in the
hypoinsulinemic STZ diabetes is associated with increased
IRS- 1 phosphorylation and PI 3-activation in liver and muscle.
By contrast, there is a striking reduction ofIRS- 1 phosphoryla-
tion and PI 3-activation in liver and muscle ofthe ob/ob mice,
and this may play an important role in this insulin resistant
state. Further studies on the coupling between PI 3-kinase acti-
vation and the metabolic downstream effects of insulin may
shed light to the pathogenesis of insulin resistance in different
disease states.
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